Chronic Obstructive Pulmonary Disease Treatment Devices Market by Product Type (Inhalers [Dry Powder Inhaler, Metered Dose Inhaler, Soft Mist Inhalers, and Others] and Nebulizers [Jet Nebulizer, Ultrasonic Nebulizer, and Mesh Nebulizer]), End-User (Hospitals & Clinics, Homecare Settings, and Others) and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a respectable CAGR forecast till 2032 owing to the increasing prevalence of chronic obstructive pulmonary disorder, high rate of tobacco smoking and air pollution, increasing awareness and screening programs, and increase in product development activities among the key market players.
The chronic obstructive pulmonary disease treatment devices market is estimated to grow at a CAGR of 6.35% during the forecast period from 2025 to 2032. The market for COPD treatment devices is expected to grow significantly due to several key factors. The increasing prevalence of chronic obstructive pulmonary disease, largely driven by aging populations, tobacco smoking, and rising air pollution, is creating a higher demand for effective respiratory support devices. Additionally, growing awareness and screening programs are leading to earlier diagnosis and treatment, further boosting the need for devices such as inhalers, oxygen concentrators, and nebulizers. Key market players are also investing in product development, introducing portable, smart, and user-friendly technologies that enhance patient compliance and enable home-based care, together driving strong growth in the COPD treatment devices market during the forecast period from 2025 to 2032.
Additionally, as per the recent data provided by the Global Burden of Disease (2023), approximately 1 in 20 people globally suffered from chronic respiratory diseases.
Furthermore, as per the recent data provided by the World Health Organization (2023), smoking was a major cause of chronic obstructive pulmonary disease, a common lung condition that led to breathing difficulties and claimed over 3 million lives annually. Approximately 392 million people had COPD, with about 75% living in low- and middle-income countries. In high-income countries, tobacco smoking was responsible for over 70% of COPD cases. As the cases of respiratory disorders rise, driven largely by smoking and environmental factors, there is a heightened need for COPD treatment devices such as nebulizers and inhalers. Nebulizers are critical in delivering medication directly to the lungs for effective symptom relief and disease management. Further, dry powder inhaler devices are used to deliver medication to the lungs, thereby escalating the overall market of COPD treatment devices.
Additionally, the increase in product development activities among the key market players is further boosting the market for COPD treatment devices. For instance, in May 2024, Medline announced the latest addition to its respiratory care portfolio, the Hudson RCI TurboMist small volume nebulizer is designed to be the fastest small volume nebulizer on the market. TurboMist delivered medication treatments in as little as three minutes.
Thus, the factors mentioned above are expected to boost the market for COPD treatment devices during the forecast period.
However, the stringent government regulations for product approval and environmental concerns associated with inhalers may limit their end-user base, thus acting as key constraints limiting the growth of the chronic obstructive pulmonary disease treatment devices.
In the product type segment of chronic obstructive pulmonary disease treatment devices, the metered dose inhaler category is expected to have a significant revenue share in the year 2024. Metered dose inhalers are a widely preferred delivery system for managing chronic obstructive pulmonary disease because of their portability, ease of use, and ability to deliver precise doses of medication directly to the lungs.
Additionally, they may be used with a variety of COPD drugs, such as steroids, including Flovent hydrofluoroalkane (HFA) and a combination of steroid/bronchodilators such as Symbicort, and combination medications. Thus, these benefits associated with the metered dose inhaler devices can increase the demand for metered dose inhaler devices, which could increase the metered dose inhaler device market overall.
However, a rise in product launches associated with the metered dose inhaler devices also drives its market growth. Additionally, in May 2025, MediPharm Labs Corp., a pharmaceutical company focused on precision-formulated cannabinoids, announced the commencement of production for its new cannabis metered dose inhalers designed for the European Union and United Kingdom. These inhalers are manufactured to meet global pharmaceutical standards and will be distributed exclusively by Blackpoint Limited, MediPharm's sales and distribution partner in those regions.
Therefore, owing to the above-mentioned factors, the metered dose inhaler category is expected to witness substantial growth in the overall chronic obstructive pulmonary disease treatment devices market during the given forecast period from 2025 to 2032.
North America is expected to dominate the overall chronic obstructive pulmonary disease treatment devices market:
Among all the regions, North America is expected to dominate the chronic obstructive pulmonary disease treatment devices market in the year 2024. The increasing prevalence of chronic obstructive pulmonary disease, along with rising comorbidities like exposure to air pollution, airborne particles, chemicals & fumes, secondhand smoke, industrial chemicals & dust, and rise in consumption of tobacco among the youth population in the US are acting as a driving growth factors for COPD treatment devices market. Furthermore, the presence of key players in the region is expected to drive the continued expansion and innovation in the market for chronic obstructive pulmonary disease treatment devices during the forecast period from 2025 to 2032.
According to data from the Centers for Disease Control and Prevention (2024), in 2022, approximately 11.6% of U.S. adults aged 18 years or older were cigarette smokers, equating to an estimated 28.8 million individuals. As per the same source, over 16 million US people were affected by smoking-related diseases. Smoking is a major risk factor associated with the development of COPD among the population.
According to the data from the American Lung Association (2024), more than 34 million people were living in the US with chronic lung diseases like COPD. In addition to this, the same source stated that in 2023, approximately 11.7 million people in the US were living with chronic respiratory disorders, which, over time, makes it harder for patients to breathe.
The rising prevalence of smoking-related diseases and chronic respiratory conditions like COPD is driving the demand for advanced treatment devices. As more individuals face difficulties with breathing and lung function, the need for effective, accessible, and innovative therapeutic solutions is growing. Increased awareness of lung health and the availability of improved technologies are further supporting the expansion of the COPD treatment device market.
Also, the presence of key market players in the region is significantly bolstering the market for chronic obstructive pulmonary disease treatment devices. For instance, in June 2024, Verona Pharma plc. announced that the U.S. Food and Drug Administration (FDA) had approved Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. The medication was designed to be administered via a standard jet nebulizer, eliminating the need for high inspiratory flow or precise hand-breath coordination, making it easier for COPD patients to use effectively.
Therefore, the interplay of all the aforementioned factors would provide a conducive growth environment for the North America region in the chronic obstructive pulmonary disease treatment devices market.
This product will be delivered within 2 business days.
The chronic obstructive pulmonary disease treatment devices market is estimated to grow at a CAGR of 6.35% during the forecast period from 2025 to 2032. The market for COPD treatment devices is expected to grow significantly due to several key factors. The increasing prevalence of chronic obstructive pulmonary disease, largely driven by aging populations, tobacco smoking, and rising air pollution, is creating a higher demand for effective respiratory support devices. Additionally, growing awareness and screening programs are leading to earlier diagnosis and treatment, further boosting the need for devices such as inhalers, oxygen concentrators, and nebulizers. Key market players are also investing in product development, introducing portable, smart, and user-friendly technologies that enhance patient compliance and enable home-based care, together driving strong growth in the COPD treatment devices market during the forecast period from 2025 to 2032.
Chronic Obstructive Pulmonary Disease Treatment Devices Market Dynamics:
According to the latest data provided by the Australian Institute of Health and Welfare, in 2022, around 8.5 million (34%) people in Australia were estimated to have chronic respiratory conditions.Additionally, as per the recent data provided by the Global Burden of Disease (2023), approximately 1 in 20 people globally suffered from chronic respiratory diseases.
Furthermore, as per the recent data provided by the World Health Organization (2023), smoking was a major cause of chronic obstructive pulmonary disease, a common lung condition that led to breathing difficulties and claimed over 3 million lives annually. Approximately 392 million people had COPD, with about 75% living in low- and middle-income countries. In high-income countries, tobacco smoking was responsible for over 70% of COPD cases. As the cases of respiratory disorders rise, driven largely by smoking and environmental factors, there is a heightened need for COPD treatment devices such as nebulizers and inhalers. Nebulizers are critical in delivering medication directly to the lungs for effective symptom relief and disease management. Further, dry powder inhaler devices are used to deliver medication to the lungs, thereby escalating the overall market of COPD treatment devices.
Additionally, the increase in product development activities among the key market players is further boosting the market for COPD treatment devices. For instance, in May 2024, Medline announced the latest addition to its respiratory care portfolio, the Hudson RCI TurboMist small volume nebulizer is designed to be the fastest small volume nebulizer on the market. TurboMist delivered medication treatments in as little as three minutes.
Thus, the factors mentioned above are expected to boost the market for COPD treatment devices during the forecast period.
However, the stringent government regulations for product approval and environmental concerns associated with inhalers may limit their end-user base, thus acting as key constraints limiting the growth of the chronic obstructive pulmonary disease treatment devices.
Chronic Obstructive Pulmonary Disease Treatment Devices Market Segment Analysis:
Chronic Obstructive Pulmonary Disease Treatment Devices Market by Product Type (Inhalers [Dry Powder Inhaler, Metered Dose Inhaler, Soft Mist Inhalers, and Others] and Nebulizers [Jet Nebulizer, Ultrasonic Nebulizer, and Mesh Nebulizer]), End-User (Hospitals & Clinics, Homecare Settings, and Others) and Geography (North America, Europe, Asia-Pacific, and Rest of the World)In the product type segment of chronic obstructive pulmonary disease treatment devices, the metered dose inhaler category is expected to have a significant revenue share in the year 2024. Metered dose inhalers are a widely preferred delivery system for managing chronic obstructive pulmonary disease because of their portability, ease of use, and ability to deliver precise doses of medication directly to the lungs.
Additionally, they may be used with a variety of COPD drugs, such as steroids, including Flovent hydrofluoroalkane (HFA) and a combination of steroid/bronchodilators such as Symbicort, and combination medications. Thus, these benefits associated with the metered dose inhaler devices can increase the demand for metered dose inhaler devices, which could increase the metered dose inhaler device market overall.
However, a rise in product launches associated with the metered dose inhaler devices also drives its market growth. Additionally, in May 2025, MediPharm Labs Corp., a pharmaceutical company focused on precision-formulated cannabinoids, announced the commencement of production for its new cannabis metered dose inhalers designed for the European Union and United Kingdom. These inhalers are manufactured to meet global pharmaceutical standards and will be distributed exclusively by Blackpoint Limited, MediPharm's sales and distribution partner in those regions.
Therefore, owing to the above-mentioned factors, the metered dose inhaler category is expected to witness substantial growth in the overall chronic obstructive pulmonary disease treatment devices market during the given forecast period from 2025 to 2032.
North America is expected to dominate the overall chronic obstructive pulmonary disease treatment devices market:
Among all the regions, North America is expected to dominate the chronic obstructive pulmonary disease treatment devices market in the year 2024. The increasing prevalence of chronic obstructive pulmonary disease, along with rising comorbidities like exposure to air pollution, airborne particles, chemicals & fumes, secondhand smoke, industrial chemicals & dust, and rise in consumption of tobacco among the youth population in the US are acting as a driving growth factors for COPD treatment devices market. Furthermore, the presence of key players in the region is expected to drive the continued expansion and innovation in the market for chronic obstructive pulmonary disease treatment devices during the forecast period from 2025 to 2032.
According to data from the Centers for Disease Control and Prevention (2024), in 2022, approximately 11.6% of U.S. adults aged 18 years or older were cigarette smokers, equating to an estimated 28.8 million individuals. As per the same source, over 16 million US people were affected by smoking-related diseases. Smoking is a major risk factor associated with the development of COPD among the population.
According to the data from the American Lung Association (2024), more than 34 million people were living in the US with chronic lung diseases like COPD. In addition to this, the same source stated that in 2023, approximately 11.7 million people in the US were living with chronic respiratory disorders, which, over time, makes it harder for patients to breathe.
The rising prevalence of smoking-related diseases and chronic respiratory conditions like COPD is driving the demand for advanced treatment devices. As more individuals face difficulties with breathing and lung function, the need for effective, accessible, and innovative therapeutic solutions is growing. Increased awareness of lung health and the availability of improved technologies are further supporting the expansion of the COPD treatment device market.
Also, the presence of key market players in the region is significantly bolstering the market for chronic obstructive pulmonary disease treatment devices. For instance, in June 2024, Verona Pharma plc. announced that the U.S. Food and Drug Administration (FDA) had approved Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. The medication was designed to be administered via a standard jet nebulizer, eliminating the need for high inspiratory flow or precise hand-breath coordination, making it easier for COPD patients to use effectively.
Therefore, the interplay of all the aforementioned factors would provide a conducive growth environment for the North America region in the chronic obstructive pulmonary disease treatment devices market.
Chronic Obstructive Pulmonary Disease Treatment Devices Market key players:
Some of the key market players operating in the chronic obstructive pulmonary disease treatment devices market include Koninklijke Philips N.V., Omron Healthcare, Inc., Aerogen, GF Health Products, Inc., BMC Medical Co., Ltd., Medtronic, Trudell Medical International, Novartis AG, AstraZeneca, Lupin, Zydus Cadila, Teva Pharmaceutical Industries Ltd, Terumo Corporation, Cipla Inc., Microlife Corporation, Honsun, Promed Technology Co. Limited, HELTMAN Medikal A.S., Pneuma Respiratory, Lepu Medical Technology (Beijing) Co., Ltd., and others.Recent Developmental Activities in the Chronic Obstructive Pulmonary Disease Treatment Devices Market:
- In August 2023, Lupin Pharmaceuticals, Inc., announced the launch of Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, for the treatment of chronic obstructive pulmonary disease (COPD) in the United States. This product is the generic equivalent of Spiriva® HandiHaler® (Tiotropium Bromide Inhalation Powder, 18 mcg/capsule) by Boehringer Ingelheim Pharmaceuticals, Inc.
- In March 2022, Novartis' Sandoz, a Swiss multinational pharmaceutical corporation, acquired UK-based delivery device development company, Coalesce Product Development Limited, developing a portfolio of inhalation devices. This includes new versions of pressurized metered dose inhalers (pMDI), breath-actuated inhalers (BAI), and pre-metered dry powder inhalers (DPI).
- In February 2022, Aptar Pharma, a global leader in drug delivery systems, services, and active material science solutions, announced the launch of HeroTracker® Sense, a novel digital respiratory health solution that transformed a standard metered dose inhaler (pMDI) into a smart, connected healthcare device.
- In February 2022, Aptar Pharma, a global leader in drug delivery systems, services, and active material science solutions, announced the launch of HeroTracker® Sense, a unique digital respiratory health solution that turns a normal metered dosage inhaler (pMDI) into a smart linked healthcare device.
Key takeaways from the chronic obstructive pulmonary disease treatment devices market report study
- Market size analysis for current chronic obstructive pulmonary disease treatment devices market size (2024), and market forecast over 8 years (2025 to 2032)
- Top key product/services developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
- Key companies dominating the chronic obstructive pulmonary disease treatment devices market
- Various opportunities available for the other competitors in the chronic obstructive pulmonary disease treatment devices market space
- What are the top-performing segments in 2024? How these segments will perform in 2032?
- Which are the top-performing regions and countries in the current chronic obstructive pulmonary disease treatment devices market scenario?
- Which are the regions and countries where companies should have concentrated on opportunities for the chronic obstructive pulmonary disease treatment devices market growth in the future?
- Chronic obstructive pulmonary disease treatment devices product providers
- Research organizations and consulting companies
- Chronic obstructive pulmonary disease treatment devices-related organizations, associations, forums, and other alliances
- Government and corporate offices
- Start-up companies, venture capitalists, and private equity firms
- Distributors and traders dealing in chronic obstructive pulmonary disease treatment devices
- Various end-users who want to know more about the chronic obstructive pulmonary disease treatment devices market and the latest developments in the chronic obstructive pulmonary disease treatment devices market
Frequently Asked Questions for the Chronic Obstructive Pulmonary Disease Treatment Devices Market:
1. What are chronic obstructive pulmonary disease treatment devices?
- The chronic obstructive pulmonary disease treatment devices are the medical devices or tools used by a patient to treat the symptoms of chronic obstructive pulmonary disease. The medication to treat COPD is administered through a device, such as inhalers, used to get relief from the symptoms of the disease.
2. What is the market for chronic obstructive pulmonary disease treatment devices?
- The chronic obstructive pulmonary disease treatment devices market is estimated to grow at a CAGR of 6.35% during the forecast period from 2025 to 2032.
3. What are the drivers for the chronic obstructive pulmonary disease treatment devices market?
- The market for COPD treatment devices is expected to grow significantly due to several key factors. The increasing prevalence of chronic obstructive pulmonary disease, largely driven by aging populations, tobacco smoking, and rising air pollution, is creating a higher demand for effective respiratory support devices. Additionally, growing awareness and screening programs are leading to earlier diagnosis and treatment, further boosting the need for devices such as inhalers, oxygen concentrators, and nebulizers. Key market players are also investing in product development, introducing portable, smart, and user-friendly technologies that enhance patient compliance and enable home-based care, together driving strong growth in the COPD treatment devices market during the forecast period from 2025 to 2032.
4. Who are the key players operating in the chronic obstructive pulmonary disease treatment devices market?
- Some of the key market players operating in the chronic obstructive pulmonary disease treatment devices market include Koninklijke Philips N.V., Omron Healthcare, Inc., Aerogen, GF Health Products, Inc., BMC Medical Co., Ltd., Medtronic, Trudell Medical International, Novartis AG, AstraZeneca, Lupin, Zydus Cadila, Teva Pharmaceutical Industries Ltd, Terumo Corporation, Cipla Inc., Microlife Corporation, Honsun, Promed Technology Co. Limited, HELTMAN Medikal A.S., Pneuma Respiratory, Lepu Medical Technology (Beijing) Co., Ltd., and others.
5. Which region has the highest share in the chronic obstructive pulmonary disease treatment devices market?
- Among all the regions, North America is expected to dominate the chronic obstructive pulmonary disease treatment devices market in the year 2024. The increasing prevalence of chronic obstructive pulmonary disease, along with rising comorbidities like exposure to air pollution, airborne particles, chemicals & fumes, secondhand smoke, industrial chemicals & dust, and a rise in consumption of tobacco among youth population in the US are acting as a driving growth factors for COPD treatment devices market. Furthermore, the presence of key players in the region is expected to drive the continued expansion and innovation in the market for chronic obstructive pulmonary disease treatment devices during the forecast period from 2025 to 2032.
This product will be delivered within 2 business days.
Table of Contents
1. Chronic Obstructive Pulmonary Disease Treatment Devices Market Report Introduction
2. Chronic Obstructive Pulmonary Disease Treatment Devices Market Executive Summary
4. Regulatory Analysis
5. Chronic Obstructive Pulmonary Disease Treatment Devices Market Key Factors Analysis
6. Chronic Obstructive Pulmonary Disease Treatment Devices Market Porter's Five Forces Analysis
7. Chronic Obstructive Pulmonary Disease Treatment Devices Market Assessment
8. Chronic Obstructive Pulmonary Disease Treatment Devices Market Company and Product Profiles
10. Project Approach
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Koninklijke Philips N.V.
- Omron Healthcare, Inc.
- Aerogen
- GF Health Products, Inc.
- BMC Medical Co., Ltd.
- Medtronic
- Trudell Medical International
- Novartis AG
- AstraZeneca
- Lupin
- Zydus Cadila
- Teva Pharmaceutical Industries Ltd
- Terumo Corporation
- Cipla Inc.
- Microlife Corporation
- Honsun
- Promed Technology Co. Limited
- HELTMAN Medikal A.S.
- Pneuma Respiratory
- Lepu Medical Technology (Beijing) Co., Ltd.
